Regulatory Page
Navigate complex regulatory landscapes seamlessly.
Strategic Leadership Page
Transform drug development for goodSolutions across all phases improve your insights, development pace, portfolio quality and submissions.Contact us How we’re changing the game Certara empowers strategic leaders to focus on...Solutions Page
Improve every phase of drug developmentEach solution assembled to meet a need. Each solution working in concert with the others. Certara seamlessly fuses science, world class modeling, technology, regulatory and...
Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses Blog Post
Abstract This Frontiers in Pharmacology article investigates how using different time-averaged exposure metrics, specifically the time-averaged concentration to event (CavTE), impacts exposure-response (ER) analyses, particularly when using logistic regression with...
Model-Informed Drug Development: Current Landscape and Future Directions Blog Post
Date: Tuesday, February 25, 2025 Time: 5:30 - 8:00pm Venue: CIC Cambridge - One Broadway, Cambridge, MA 02142 Summary Join us for an interactive event focused on Model-Informed Drug Development...
Anonymization vs. Redaction of Clinical Trial Data Blog Post
Honz Slipka January 17, 2025 The vernacular for disclosing pharmaceutical clinical trial results to the public may seem just as confusing as the process! Some people use “anonymization” and “redaction”...
Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals Blog Post
Abstract Background Coronavirus disease 2019 (COVID-19) remains a major public health concern, with continued resurgences of cases and substantial risk of mortality for hospitalized patients. Remdesivir has become standard-of-care for...
Dose Guidance for a Novel Combination Therapy to Treat Head and Neck Squamous Cell Carcinoma (HNSCC) for Patients with HRAS/PIK3CA Variants Using a Quantitative Systems Pharmacology (QSP) Model Blog Post
Download PDF You May Also Like AllModeling and Simulation - QSP QSP Summit 2025: A New Standard in the Future of Drug DevelopmentQSP Summit 2025: A New Standard in the...
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results Blog Post
January 15, 2025 Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted EBITDA within Guidance Range of $120 million to $124 million RADNOR, PA — January 15, 2025...
